Etiology, Pathophysiology, and Treatment of Atrial Fibrillation Part 1

被引:18
作者
Arortow, Wilbert S. [1 ]
机构
[1] New York Med Coll, Westchester Med Ctr, Div Cardiol, Dept Med, Valhalla, NY 10595 USA
关键词
atrial fibrillation; beta blockers; stroke; cardiovascular disease; cardioversion; digoxin; calcium channel blockers; radiofrequency catheter ablation; pacemakers; antiarrhythmic drugs;
D O I
10.1097/CRD.0b013e31816de1e3
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Atrial fibrillation (AF) is associated with a higher incidence of mortality, stroke, and coronary events than is sinus rhythm. AF with a rapid ventricular rate may cause a tachycardia-related cardiomyopathy. Immediate direct-current cardioversion should be performed in patients with AF and acute myocardial infarction, chest pain due to myocardial ischemia, hypotension, severe heart failure, or syncope. Intravenous beta blockers, verapamil, or diltiazem may be given to immediately slow a very rapid ventricular rate in AF. An oral beta blocker, verapamil, or diltiazem should be used in persons with AF if a fast ventricular rate occurs at rest or during exercise despite digoxin. Amiodarone may be used in selected patients with symptomatic life-threatening AF refractory to other drugs. Digoxin should not be used to treat patients with paroxysmal AF. Nonpharmacologic therapies should be used in patients with symptomatic AF in whom a rapid ventricular rate cannot be slowed by drugs. This is part 1 of a 2-part review of the etiology, pathophysiology, and treatment of atrial fibrillation. The second part will be published in the subsequent issue of Cardiology in Review.
引用
收藏
页码:181 / 188
页数:8
相关论文
共 50 条
[31]   Treatment of atrial fibrillation [J].
Benussi, S .
EUROPEAN JOURNAL OF CARDIO-THORACIC SURGERY, 2004, 26 :S39-S41
[32]   Update on atrial fibrillation: Part I [J].
Savelieva, Irina ;
Camm, John .
CLINICAL CARDIOLOGY, 2008, 31 (02) :55-62
[33]   Morphology and pathophysiology of target anatomical sites for ablation procedures in patients with atrial fibrillation. Part I: Atrial structures (atrial myocardium and coronary sinus) [J].
Corradi, Domenico ;
Callegari, Sergio ;
Gelsomino, Sandro ;
Lorusso, Roberto ;
Macchi, Emilio .
INTERNATIONAL JOURNAL OF CARDIOLOGY, 2013, 168 (03) :1758-1768
[34]   AGE-RAGE Stress in the Pathophysiology of Atrial Fibrillation and Its Treatment [J].
Prasad, Kailash .
INTERNATIONAL JOURNAL OF ANGIOLOGY, 2020, 29 (02) :72-80
[35]   Recent Insights into the Pathophysiology of Atrial Fibrillation [J].
Van Wagoner, David R. .
SEMINARS IN THORACIC AND CARDIOVASCULAR SURGERY, 2007, 19 (01) :9-15
[36]   Epidemiology, etiology and mechanism of atrial fibrillation [J].
Le Fieuzey, Jean-Yves .
BULLETIN DE L ACADEMIE NATIONALE DE MEDECINE, 2011, 195 (4-5) :953-960
[37]   Atrial fibrillation and type 2 diabetes: Prevalence, etiology, pathophysiology and effect of anti-diabetic therapies [J].
Bell, David S. H. ;
Goncalves, Edison .
DIABETES OBESITY & METABOLISM, 2019, 21 (02) :210-217
[38]   Patient-centered treatment in atrial fibrillation [J].
Cox, Mary C. ;
Gulati, Vijay K. .
JAAPA-JOURNAL OF THE AMERICAN ACADEMY OF PHYSICIAN ASSISTANTS, 2016, 29 (12)
[39]   Right Atrial Appendage: Forgotten Part of the Heart in Atrial Fibrillation [J].
Ozer, Orhan ;
Sari, Ibrahim ;
Davutoglu, Vedat .
CLINICAL AND APPLIED THROMBOSIS-HEMOSTASIS, 2010, 16 (02) :218-220
[40]   Hypertension and Atrial Fibrillation: An Intimate Association of Epidemiology, Pathophysiology, and Outcomes [J].
Dzeshka, Mikhail S. ;
Shahid, Farhan ;
Shantsila, Alena ;
Lip, Gregory Y. H. .
AMERICAN JOURNAL OF HYPERTENSION, 2017, 30 (08) :733-755